2018 Full year and fourth quarter
We will announce our full year and fourth quarter 2018 results at 12:00 GMT, 07:00 EST on Wednesday 06 February. Following the announcement there will be a webcast, hosted by Emma Walmsley, CEO; Simon Dingemans, CFO; and other members of the CET at 14:00 GMT, 09:00 EST.
2013 Third Quarter - released 23 October 2013
Simon Dingemans, CFO, discusses our third quarter results 2013.
2013 Second Quarter - released 24 July 2013
Simon Dingemans, CFO, discusses our second quarter results 2013.
2013 First Quarter - released 24 April 2013
Simon Dingemans, CFO, discusses our first quarter results 2013.
2012 Fourth Quarter - released 06 February 2013
Simon Dingemans, CFO, and Sir Andrew Witty, CEO, discuss our fourth quarter results 2012.
- Core EPS of 112.7p and returns of £6.3bn to shareholders
- 2012 dividend of 74p (+6%)
- Group sales -1%; flat excluding disposals of OTC brands
- Successful R&D delivery: six new drugs filed since start of 2012
Other key information
Speeches & presentations
Search through our archive of speeches and presentations from conferences and events
Keep up to date with our news and recent announcements
A snapshot of our medicines and vaccines currently in development across three stages: phase I, phase II and phase III
Corporate Executive Team
The Corporate Executive Team manages our activities, and each member is responsible for a specific part of the business